Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Michele Ghielmini, Shu Fang Hsu Schmitz, Sergio B. Cogliatti, Gabriella Pichert, Jörg Hummerjohann, Ursula Waltzer, Martin F. Fey, Daniel C. Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof, Thomas Cerny

Research output: Contribution to journalArticle

Abstract

The potential benefits of extended rituximab treatment have been investigated in a randomized trial comparing the standard schedule with prolonged treatment in 202 patients with newly diagnosed or refractory/relapsed follicular lymphoma (FL). All patients received standard treatment (rituximab 375 mg/m2 weekly × 4). In 185 evaluable patients, the overall response rate was 67% in chemotherapy-naive patients and 46% in pretreated cases (P <.01). Patients responding or with stable disease at week 12 (n = 151) were randomized to no further treatment or prolonged rituximab administration (375 mg/m2 every 2 months for 4 times). At a median follow-up of 35 months, the median event-free survival (EFS) was 12 months in the no further treatment versus 23 months in the prolonged treatment arm (P = .02), the difference being particularly notable in chemotherapy-naive patients (19 vs 36 months; P = .009) and in patients responding to induction treatment (16 vs 36 months; P = .004). The number of t(14;18)-positive cells in peripheral blood (P = .0035) and in bone marrow (P = .0052) at baseline was predictive for clinical response. Circulating normal B lymphocytes and immunoglobulin M (IgM) plasma levels decreased for a significantly longer time after prolonged treatment, but the incidence of adverse events was not increased. In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly Improves the EFS.

Original languageEnglish
Pages (from-to)4416-4423
Number of pages8
JournalBlood
Volume103
Issue number12
DOIs
Publication statusPublished - Jun 15 2004

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule'. Together they form a unique fingerprint.

  • Cite this

    Ghielmini, M., Schmitz, S. F. H., Cogliatti, S. B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M. F., Betticher, D. C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D., & Cerny, T. (2004). Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood, 103(12), 4416-4423. https://doi.org/10.1182/blood-2003-10-3411